<DOC>
	<DOCNO>NCT00285818</DOCNO>
	<brief_summary>The purpose study see whether medication mifepristone effective tolerable treatment increase clinical effectiveness electroconvulsive therapy ( ECT ) protect cognitive function ECT . Both Mifepristone ECT appear normalize hyperfunctioning hypothalmic-pituitary-adrenal ( HPA ) axis , find among patient major depression refer ECT . The combination two treatment major depression may lead rapid clinical response ECT alone . Additionally , appear connection pre-ECT high cortisol level due HPA axis hyperfunctioning post-ECT cognitive impairment . Administration mifepristone prior ECT treatment may reduce cortisol level reduce incidence cognitive impairment observe ECT .</brief_summary>
	<brief_title>Mifepristone Treatment Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT</brief_title>
	<detailed_description>Patients refer Stanford ECT Service provide inform consent study screen eligibility . Day -4 0 : Screening ( visit 1 ) occur three six day prior first ECT treatment . Screening procedure include : Psychiatric interview rating ( include MINI , Hamilton Depression Rating Scale Clinician 's Global Impression ) review/retrieval result pre-ECT physical exam , ECG , chest x-ray , laboratory evaluation ( include comprehensive metabolic panel , comprehensive blood count , urine toxicology ) , vital sign subject 's medical record . A urine pregnancy test include female childbearing potential . Concomitant medication pre-existing health issue record . Subjects deem eligible study undergo battery neuropsychiatric assessment admit GCRC collection blood sample measure adrenocorticotropin ( ACTH ) cortisol level . These sample collect hourly begin 1pm end 4pm . Day 1 : Subjects randomize 1:1 receive either mifepristone 600mg placebo day bedtime begin two day prior first ECT treatment . Subjects administer study medication Day 1 Day 8 . Day 3 : Subjects interview Hamilton Depression Rating Scale Clinician 's Global Impression first ECT treatment . Day 11 : ( visit 2 ) assessment include psychiatric rating ( include Hamilton Depression Rating Scale Clinician 's Global Impression ) battery neuropsychiatric assessment . Adverse event concomitant medication review record . Subjects admit GCRC collection blood sample measure ACTH cortisol level . Samples collect hourly begin 1pm end 4pm . Day 18 : ( visit 3 ) assessment include psychiatric rating ( include Hamilton Depression Rating Scale Clinician 's Global Impression ) . Adverse event concomitant medication review record . Clinical laboratory assessment complete ( include urine pregnancy test female , comprehensive metabolic panel , comprehensive blood count , urine toxicology , ECG . ) Final visit : ( visit 4 ) occur 24-72 hour last ECT treatment . Assessments include psychiatric rating ( include Hamilton Depression Rating Scale Clinician 's Global Impression ) battery neuropsychiatric assessment . Adverse event concomitant medication review record . A urine pregnancy test complete female . In addition ECT treatment consent , follow material collect participant 's medical record every ECT treatment : ECT treatment order , ECT procedure note result pre-ECT Montgomery-Asberg Depression Rating Scale ( MADRS ) . ECT treatment Stanford 's ECT Service run every Monday , Wednesday Friday .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>To consider participation study , subject must meet following criterion : 1 . Meets DSMIV criterion Major Depressive Episode without psychotic feature . 2 . 1875 year age able provide legal consent . 3 . Referred Stanford ECT service treat physician bilateral electroconvulsive therapy inpatient hospitalization . 4 . Completed process consent clinical use ECT accord California State law . 5 . Females childbearing potential must use doublebarrier method contraception study 30 day study ( modified 62003 ) Subjects exclude participation meet follow criterion : 1 . Treatment ECT 6 month prior screen . 2 . Meets criteria drug alcohol abuse dependence 6 month prior screen . 3 . Use alcohol illegal drug within seven day randomization study . 4 . Presence unstable untreated cardiovascular disease , hypertension , endocrine disorder determine investigator . 5 . Use antipsychotic , antidepressant , prescription medication unless dose stable least 7 day prior randomization . 6 . Use investigational treatment within 30 day randomization . 7 . Current pregnancy . 8 . Current lactation . 9 . Previous allergic reaction mifepristone drug similar chemical structure . ( added 62003 ) 10 . Use oral contraceptive drug may result adverse drugmifepristone interaction effect . A 30day wash period oral contraceptive require mifepristone begin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>